Skip to main content

Advertisement

SpringerLink
Log in

Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Background/aim

Ixazomib, lenalidomide, and dexamethasone (IRd) have proven efficacy and an excellent safety profile in relapsed and/or refractory multiple myeloma (RRMM). However, there are limited reports on the real-world safety and effectiveness of IRd regimens in Asian patients with RRMM.

Patients and methods

This was a retrospective study of 60 patients with RRMM who were treated with IRd.

Results

The median patient age was 68 years. Forty percent of patients did not meet the eligibility criteria for the TOURMALINE-MM1 trial. Patients received a median of one prior line of therapy. Non-hematologic adverse events (AEs) were more common than hematologic AEs. The most common AE was skin rash, followed by gastrointestinal toxicities. Most grade 3 or higher AEs were observed in less than 5% of the patients, except for skin rashes and infections. IRd therapy did not aggravate peripheral neuropathy (PN) in 20 of the 24 patients with pre-existing peripheral neuropathy. The overall response rate was 85%. After a median follow-up of 26.3 months, the median progression-free survival was 25.9 months and overall survival was not reached.

Conclusion

Ixazomib and Rd combination therapy had a comparable toxicity profile and effectiveness in real-world RRMM patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410–27. https://doi.org/10.1016/S0140-6736(21)00135-5.

    Article  Google Scholar 

  2. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142–52. https://doi.org/10.1056/NEJMoa1411321.

    Article  CAS  Google Scholar 

  3. Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621–34. https://doi.org/10.1056/NEJMoa1516282.

    Article  CAS  Google Scholar 

  4. Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–31. https://doi.org/10.1056/NEJMoa1607751.

    Article  CAS  Google Scholar 

  5. Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–31. https://doi.org/10.1056/NEJMoa1505654.

    Article  CAS  Google Scholar 

  6. Chari A, Romanus D, Palumbo A, Blazer M, Farrelly E, Raju A et al. Randomized clinical trial representativeness and outcomes in real-world patients: comparison of 6 hallmark randomized clinical trials of relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(1):8–17 e6. https://doi.org/10.1016/j.clml.2019.09.625.

  7. Chari A, Richardson PG, Romanus D, Dimopoulos MA, Sonneveld P, Terpos E, et al. Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and Ird. Expert Rev Hematol. 2020;13(4):421–33. https://doi.org/10.1080/17474086.2020.1729734.

    Article  CAS  Google Scholar 

  8. Vania TM, Hungria MP, Lee HC, Abonour R, Rifkin RM, Terpos E, et al. Real-world (RW) multiple myeloma (MM) patients (Pts) remain under-represented in clinical trials based on standard laboratory parameters and baseline characteristics: analysis of over 3,000 pts from the insight MM global, prospective. Observat Study Blood. 2019;134:1887.

    Google Scholar 

  9. Takakuwa T, Yamamura R, Ohta K, Kaneko H, Imada K, Nakaya A, et al. Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: a multicenter retrospective analysis. Eur J Haematol. 2021;106(4):555–62. https://doi.org/10.1111/ejh.13586.

    Article  CAS  Google Scholar 

  10. Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P. ASH/FDA panel on clinical endpoints in multiple myeloma. Clinically relevant end points and new drug approvals for myeloma. Leukemia. 2008;22(2):231–9. https://doi.org/10.1038/sj.leu.2405016

  11. Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011;117(18):4696–700. https://doi.org/10.1182/blood-2010-10-300970.

    Article  CAS  Google Scholar 

  12. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–46. https://doi.org/10.1016/S1470-2045(16)30206-6.

    Article  Google Scholar 

  13. Lee JH, Kim SH. Treatment of relapsed and refractory multiple myeloma. Blood Res. 2020;55(S1):S43–53. https://doi.org/10.5045/br.2020.S008.

    Article  Google Scholar 

  14. Richardson PG, Kumar SK, Masszi T, Grzasko N, Bahlis NJ, Hansson M, et al. Final overall survival analysis of the TOURMALINE-MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2021;39(22):2430–42. https://doi.org/10.1200/JCO.21.00972.

    Article  CAS  Google Scholar 

  15. Hou J, Jin J, Xu Y, Wu D, Ke X, Zhou D, et al. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China continuation study. J Hematol Oncol. 2017;10(1):137. https://doi.org/10.1186/s13045-017-0501-4.

    Article  CAS  Google Scholar 

  16. Varga G, Nagy Z, Demeter J, Kosztolanyi S, Szomor A, Alizadeh H, et al. Real world efficacy and safety results of ixazomib lenalidomide and dexamethasone combination in relapsed/refractory multiple myeloma: data collected from the hungarian ixazomib named patient program. Pathol Oncol Res. 2019;25(4):1615–20. https://doi.org/10.1007/s12253-019-00607-2.

    Article  CAS  Google Scholar 

  17. Cohen YC, Magen H, Lavi N, Gatt ME, Chubar E, Horowitz N, et al. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study. Ann Hematol. 2020;99(6):1273–81. https://doi.org/10.1007/s00277-020-03985-9.

    Article  CAS  Google Scholar 

  18. Ziff M, Lawson G, De-Silva D, Cheesman S, Kyriakou C, Mahmood S, et al. Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set. Leuk Lymphoma. 2021;62(5):1243–6. https://doi.org/10.1080/10428194.2020.1864356.

    Article  CAS  Google Scholar 

  19. Maouche N, Kishore B, Jenner MW, Boyd K, Bhatti Z, Bird SA, et al. Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (>/=2nd relapse) refractory myeloma: a multicenter real world UK experience. Leuk Lymphoma. 2021;62(6):1396–404. https://doi.org/10.1080/10428194.2020.1864355.

    Article  CAS  Google Scholar 

  20. Terpos E, Ramasamy K, Maouche N, Minarik J, Ntanasis-Stathopoulos I, Katodritou E, et al. Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. Ann Hematol. 2020;99(5):1049–61. https://doi.org/10.1007/s00277-020-03981-z.

    Article  CAS  Google Scholar 

  21. Minarik J, Pika T, Radocha J, Jungova A, Straub J, Jelinek T, et al. Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice. BMC Cancer. 2021;21(1):73. https://doi.org/10.1186/s12885-020-07732-1.

    Article  CAS  Google Scholar 

  22. Duarte PJ, Schutz NP, Ochoa P, Yantorno S, Orlando S, Lopresti S et al. Real-world outcomes for the treatment of relapsed/refractory multiple myeloma patients with lenalidomide-dexamethasone combinations in a Latin American country. A retrospective cohort study from grupo argentino de mieloma multiple. Expert Rev Hematol. 2021;14(3):315–22. https://doi.org/10.1080/17474086.2021.1886073.

  23. Hajek R, Minarik J, Straub J, Pour L, Jungova A, Berdeja JG, et al. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. Future Oncol. 2021;17(19):2499–512. https://doi.org/10.2217/fon-2020-1225.

    Article  CAS  Google Scholar 

  24. Davies F, Rifkin R, Costello C, Morgan G, Usmani S, Abonour R, et al. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. Ann Hematol. 2021;100(9):2325–37. https://doi.org/10.1007/s00277-021-04534-8.

    Article  CAS  Google Scholar 

  25. Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36(8):728–34. https://doi.org/10.1200/JCO.2017.76.5032.

    Article  CAS  Google Scholar 

  26. Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L, et al. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood. 2017;130(24):2610–8. https://doi.org/10.1182/blood-2017-06-791228.

    Article  CAS  Google Scholar 

  27. Mateos MV, Masszi T, Grzasko N, Hansson M, Sandhu I, Pour L et al. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. Haematologica. 2017;102(10):1767–75. https://doi.org/10.3324/haematol.2017.170118.

  28. Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res. 2011;17(9):2734–43. https://doi.org/10.1158/1078-0432.CCR-10-1950.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (No. NRF-2016R1A5A2007009 and No. NRF-2017R1C1B5014853). This study would not have been possible without the cooperation of the Korean Multiple Myeloma Working Party. The preliminary results of this study have been presented at the 2021 Korean Society of Hematology International Conference and the 62nd Annual meeting, Seoul, Republic of Korea.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Dong-A University College of Medicine, Busan, Republic of Korea

    Ji Hyun Lee, Sung-Hyun Kim & Hye Ryeon Kim

  2. Department of Hematology, Seoul St. Mary’s Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

    Chang-Ki Min

  3. Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Republic of Korea

    Je-Jung Lee

  4. Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Medical Research Institute, Pusan National University Hospital, Busan, Republic of Korea

    Ho-Jin Shin

  5. Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea

    Jae-Cheol Jo

  6. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea

    Ji Yun Lee

  7. Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Kyungpook National University, 130, Dongduk-Ro, Jung-Gu, Daegu, 41944, Republic of Korea

    Joon Ho Moon

  8. Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, 81, Irwon-Ro, Gangnam-Gu, Seoul, 06351, Republic of Korea

    Kihyun Kim

Authors
  1. Ji Hyun Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sung-Hyun Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hye Ryeon Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chang-Ki Min
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Je-Jung Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ho-Jin Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jae-Cheol Jo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ji Yun Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Joon Ho Moon
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kihyun Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Study design: JHL and KK. Patient enrollment and data collection: JHL, S-HK, HRK, JHM, C-KM, J-JL, H-JS, J-CJ, JYL, and KK. Data analysis: JHL and S-HK. Paper writing: JHL, JHM, and KK. Paper revisions: All authors.

Corresponding authors

Correspondence to Joon Ho Moon or Kihyun Kim.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to declare.

Ethical approval

This study was approved by the Institutional Review Board of each participating hospital, in accordance with the Declaration of Helsinki.

Informed consent

Informed consent was obtained from all patients for being included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, J.H., Kim, SH., Kim, H.R. et al. Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma. Int J Hematol 117, 225–235 (2023). https://doi.org/10.1007/s12185-022-03479-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-022-03479-6

Keywords

Search

Navigation